Anteris Technologies Secures CMS Reimbursement for Pivotal PARADIGM Trial

Key Facts

Anteris Technologies has announced that it secured U.S. Medicare reimbursement eligibility for its global pivotal PARADIGM Trial. The coverage falls under the CMS National Coverage Determination 20.32, specifically targeting procedures related to TAVR technology. This reimbursement support is expected to significantly facilitate the activation of U.S. clinical sites and streamline patient enrollment processes. By securing government funding for these procedures, the company reduces the financial friction typically associated with large-scale clinical trials. The PARADIGM Trial is a critical component of the company's path toward regulatory approval for its structural heart devices. This development is viewed as a positive milestone for the biotech firm's operational timeline and clinical strategy.